Business Context and Reporting Period
Company: Daxor Corp (DXR)
Filing Type: Form 8-K (Current Report)
Date: April 23, 2020
Business Overview: An investment company with operations in innovative medical instrumentation and biotechnology, specifically focused on blood volume measurement.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain comprehensive financial statements. No data is provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this specific document.
Material Changes
New Contract Award: On April 23, 2020, the United States Department of Defense (DOD) awarded the Company a contract valued at $1.1 million.
Contract Scope: Development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the DOD contract award.
Risks and Contingencies: No specific risks, contingencies, or forward-looking guidance are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Verify the terms and duration of the $1.1 million DOD contract via the attached press release (Exhibit 99.1).
- Confirm the timeline for the development and deployment phases of the Blood Volume Analyzer.
- Review the Company's most recent 10-Q or 10-K for current liquidity and cash position to assess the ability to fund the new contract.
- Monitor future filings for revenue recognition related to this specific government contract.